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1. Introduction 
Lack of curative treatment in most of neurological disorder has been a permanent 
frustration for almost all of us. Fortunately, good news about novel therapeutic approaches 
and its excellent responses are gradually arriving and today we can celebrate some 
therapeutic advances such as: cytokines-based therapies for immune-mediated 
inflammatory myopathies; myoclonal antibodies for the treatment of certain types of 
immune-mediated inflammatory neuropathies, myopathies, and T-cell mediated disorders; 
enzyme replacement therapy for Pompe’s disease. Non-ergoline dopamine agonist and 
deep-brain stimulation of subthalamic nucleus and the globus pallidus internus in 
Parkinson disease, and immunomodulatory agents for multiple sclerosis among others and 
some exciting therapeutic approaches will come very soon for example: antisense 
oligonucleotides in Duchenne muscular dystrophy. Stem-cell therapy and gene therapy for 
inherited neuromuscular disorders, up-regulation of fetal isoforms in hereditary disorders 
such as: myophophorylase deficiency, and novel forms of neuromodulation. Unfortunately, 
for treatment of epilepsy secondary to neurocysticercosis (NC) no therapeutic advances has 
been reported and apart from carbamazepine (CBZ) and valproic acid (VA) no other 
antiepileptic drug (AED) has proven better efficacy. Although, levetiracitam seems to be as 
well as CBZ and VA it is not available in rural clinics and in most of the public hospitals 
from developing countries where NC is endemic. Therefore, several millions of epileptic 
patients cannot reach levetiracitam worldwide.  
Pharmacoresistance in developed countries, lack of AED or poor access to the AED in 
developing countries continue playing an important role in the high prevalence of difficult–
to-control adult epilepsy and are even more 45% of the epileptic population continue 
experience regular seizures then the only choice that we have is to improve treatment 
approaches to NC hoping that it may contribute to a better control of epilepsy. 
Neurocysticercosis is the leading cause of epilepsy in developing countries and it is 
becoming one of the most common causes of epilepsy in developed countries due to 
globalization. It is a preventable and potentially eradicable neurological disorder. [Roman 
2000].  At the present moment, treatment of NC in patients presenting epilepsy still has 
some controversial aspects (Goldberg, 1984; Moodley & Moosa, 1989; Kramer, 1990; 
Rajshekhar, 1991; Carpio et al. 1995). Apart from dosages of anti-parasitic drugs and its 
duration; whether or not to use albendazole or praziquantel and how to use it, as part of 
the treatment for NC, is not certain. Based on findings from other researchers and our 
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results, we will establish a clear-cut guideline for the best management of this problem in 
this chapter.  
Tenia solium is transmitted among humans and between humans and pigs. Taeniosis is 
acquired only by humans after eating raw or undercooked pork meat contaminated with 
cysticerci, the larval form of parasite. When ingested, the cysticerci migrate to the intestine 
of humans where they establish and become adults. These adult worms shed eggs in human 
feces that can infect other humans and pigs by direct contact or by indirect contamination of 
water or food. In developing countries, pigs are often allowed to roam freely and they can 
easily eat human feces. Ingested eggs result in larvae migrating to different parts of the pig 
or the human and forming cysts. A principle site of migration in humans is the CNS. 
Human NC occurs when the cysts develop in the brain or spinal cord. Seizures are the most 
common clinical presentation of NC, affecting from 66% to 90% of cases (Carpio & Hauser, 
2002; Wallin & Kurtzke; 2004). In addition to acute seizures and epilepsy, NC can manifest 
with severe headaches, obstructive hydrocephalus, chronic meningitis, symptoms 
intracranial hypertension, and dementia (Prabhakar & Singh, 2002). Based on the stage of 
the intracerebral parasite on CT/MRI, then NC can be classified as “active”: when scolex of 
parasite is visible within a cyst on imagenology, colloidal stage: when the cyst is filled with 
turbid fluid and there is an intense inflammatory response in the surrounding parenchyma 
also in imagenology, and calcified or “inactive”:  when parasite remnants form a 
mineralized granuloma (Bhigjee & Rosemberg, 2006).  
The manner in which NC presents clinically and the severity of the symptoms (from 
asymptomatic to severe) are thought to depend both on the location of the cysts in the brain 
(e.g., intraventricular, parenchymal, subarachnoid), their developmental stage and the types 
and degree of immune response stimulated by the cysts (Garcia & Del Brutto, 2000, 2005; 
Chavarria et al., 2005; Uddin et al, 2005; Bhigjee & Rosemberg, 2006). The initial vesicular 
stage is usually not associated with an inflammatory response as you can see in Figure 1, 
which typically occurs later when the cyst degenerates (colloidal stage) by natural causes or 
due to antiparasitic effect. Astrocytes would play an important role in initiating the immune 
response to a degenerating cysterci by secreting chemokine in response to TNF-α from 
monocytes stimulated by larval antigen (Uddin et al., 2005). Over-expression of the immune 
response stimulated by degenerating cysterci, which is characterized primarily by a Th1-
type cytokine profile, can result in chronic inflammation and granuloma formation of the 
type seen in NC patients with calcified lesions (Uddin et al., 2005). More severe symptoms 
were shown to be associated with an increased number of inflammatory cells in the CNS of 
patients with NC (Chavarria et al., 2005). Acute seizures can be seen associated with 
vesicular or colloidal cysts whereas epilepsy is often found in association with calcified cysts 
(Bhigjee & Rosemberg, 2006). The incubation period of cysticercosis is extremely variable 
(Prabhakar & Singh, 2002), and the proportion of infected cases who develop NC is 
unknown (Bern et al., 1999; Carpio & Hauser, 2002).  
The duration of NC-associated symptoms and the proportion of cases with full recovery 
from symptoms with or without treatment remain ill-defined (Bern et al., 1999; Prabhakar & 
Singh, 2002). The prevalence of epilepsy in Sub-Saharan Africa has been estimated to be two 
to three times higher than that found in industrialized countries, a difference that may be 
attributed, in part, to NC (Preux & Druet-Cabanac, 2005). 
Diagnostic criteria for NC have been well-established based on Imagenology. Categories of 
absolute criteria (patognomonic) are acceptable when the histological demonstration of the 
parasite from a biopsy of the brain or spinal cord lesion is made, or cystic lesion showing the 
head of the parasite (scolex) on CT or MRI is seen, or when sub retinal parasites can be 
visualized by fundoscopy examination. In places where a CT scan is not available, plain X 
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rays of muscular tissues in the limbs showing “cigar shape” calcifications or plain skull X 
rays with intracranial calcifications (between 1 to 10 mm of diameter) can be useful to 
support the diagnosis; other options such as Major, Minor or Epidemiological criteria's can 
be reviewed in the original article (Del Brutto et al., 2001).  
1.1 Should be treated neurocysticercosis in epileptic patients? 
Neurocysticercosis is a zoonotic infection of central nervous system (CNS) caused by the larval 
stage (Cysticercus cellulose) of the pig tapeworm Taenia Solium and it is the most common 
helminth to produce CNS infection in human beings.  Some authors consider anti-parasitic 
treatment as a cause epilepsy and recommend do not use it. Researches supporting the theory 
of “non-antiparasitic drugs” basically defend four hypotheses: First, the sudden destruction of 
parasites may trigger an inflammatory reaction that precipitates seizures and transient 
neurologic effects, mostly headache and vomiting. Second, in a considerable number of 
patients, neurocysticercosis is clinically silent, producing only occasional seizures that are easy 
to manage with anticonvulsive therapy; thus, exposing these patients to the risk of adverse 
reactions to cysticidal therapy may be unnecessary. Third, in some cases, the cysticerci will be 
adequately eliminated either by the host's immune response or by spontaneous regression. 
Finally, the physical elimination of a parasite, objectively confirmed by neuroimaging studies, 
does not in itself mean that the patient's neurologic dysfunction will improve. (Sotelo, 2004).  
Serum levels of phenytoin and carbamazepine may also be lowered as the result of 
simultaneous praziquantel administration (Bettencourt et al., 1992).  It is also true that T 
solium may remain asymptomatic from months to years until a diagnosis is made incidentally 
when neuroimaging study is performed. Symptoms and signs are related both to the parasite 
which can show a different biological pattern from one place to another and to the 
inflammatory-immunological response of the host (Foyaca-Sibat & Ibañez-Valdés, 2002, 2008). 
The introduction of praziquantel (PZQ) by Robles, (1979) and albendazole (ABZ) by 
Escobedo, (1987) as specific antiparasitic agents was enthusiastically adopted by most of our 
medical community; it’s represented the beginning of a revolutionary process to eradicate 
NC. Nevertheless, some authors reported cases series where they noted that some types of 
parenchymal NCC can resolve on imaging studies without being treated with antiparasitic 
drugs soon after the initial descriptions of successful use of praziquantel and albendazole in 
neurocysticercosis were done (Miller, 1983; Mitchell, 1988)    
 We studied 3 762 epileptic patients from rural areas with well documented NC during the 
past 14 years and our experience clearly indicates that anti-parasitic medication can be 
prescribed in most of epileptic patients.  
1.1.1 From our previous studies 
From June 1999 to July 2001, one hundred eighty nine patients fulfilling the clinical criteria 
of uncontrolled epileptic seizures due to NC were identified prospectively for the study 
among patients referred to neurology clinic at Umtata General Hospital (South Africa) from 
rural clinics. Most of those patients presented with an associated HIV infection, pulmonary 
tuberculosis and some of them a history of haematuria probably due to schistosomiasis. 
After the CT scan of the brain, eligible patients (n=163) had active and/or chronic forms of 
NC and uncontrolled tonic-clonic generalized seizures in spite of taking the regular 
antiepileptic treatment (phenytoin 300 mg orally at night). After neurological evaluation of 
all participants, nobody had previous history of neurological disorder apart from epilepsy 
and those with concomitant disorders such: metabolic disorders, cerebrovascular diseases, 
meningoenchephalitis, and head injuries were excluded. No patients receiving treatment for 
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any other disease requiring immunomodulatory agents within the past six months were 
admitted to the study.  
Other exclusion criteria included alternative cause for intracranial calcifications or suspicion 
of tuberculomas, pyogenic brain abscesses, mycotic granulomas, and primary or metastatic 
brain tumors. Apart from antiepileptic drugs, steroids medications and anti-parasite 
treatment, other concomitant treatment was prohibited for patient while participating in the 
study. The study was designed as: a randomized, placebo-controlled double blind clinical 
trial over a redesigned 1-years period. Patients were assigned to receive 400 mg of 
phenytoin every night, 40 mg of prednisone orally during five days, and one day treatment 
with 100 mg/Kg of praziquantel divided in four doses to be given every two hours (group 
1) or only 400 mg of phenytoin at night during the same period of time (group 2) according 
to block-randomization procedure.  
1.1.2 Outcomes measures 
Response to antiepileptic medication and an associated anti-parasite treatment were 
assessed with the neurology UGH scale in which 0 is the lowest: no change, I: equivalent to 
decreased frequency of seizures II: diminished frequency and duration of seizures III: the 
highest free of seizures Each patient received the same supporting treatment and was 
encouraged to eat a rich carbohydrate meal and were evaluated throughout the study by the 
same personnel. Two-side t. Test was used to analyses the primary outcome measure 
between baseline and the end of the treatment. 
1.1.3 Results and comments 
Absolute criteria for NC based on neuroimaging studies were present in all selected patients 
considering the cystic lesion with scolex as pathognomonic.  
The efficacy analysis included 71 patients (36 males and 35 females, mean age 38,27, years, 
range 13 to 59) treated with phenytoin/praziquantel/prednisone (PPP) and 72 (32 women 
and 40 men, mean age 49,28 years, range 13 to 62) with phenytoin (P) only. A mild 
improvement in both groups at the beginning was observed but at baseline no difference in 
UGH scale was found between groups treated with PPP and a group treated with P (PPP 
0.06 ±1. 02 versus P 0.02 ±0. 09, p=0. 56). One month after the treatment with praziquantel, 
improvement was seen when comparing UGH scale results between two different groups 
(mean SE, 0,74 ± 0.14 versus -0.2 ± 0.2, 0.63 ± 0.25, mean difference ± SE; p=0. 005). In the PPP 
group 73 % improved in frequency and duration of epileptic attacks. We found that odds 
ratio of 0. 74 in P group, and 0.43 in PPP with 82 % of the confidence interval (See table I) 
In 2001 we have not a clear idea about HIV/AIDS and its role in the pathogenesis of epilepsy 
and that conclusion was not 100% confident. Therefore, years later we designed another study 
to investigate this factor and our finding will be discussed later in this chapter. 
2. Approach to patients presenting epileptic seizures and neurocysticercosis 
Some colleagues still have problems with differentiated epileptic seizures from epilepsy.  
Remember that epilepsy is a chronic brain disorders characterized by epileptic seizures 
while seizures can be caused or triggered by other causes no related to chronic brain 
pathology and they are not recurrent in absent of those causes. Hypoglycemia is a good 
example as a cause of epileptic seizures. Seizures respond well to a single antiepileptic, and 
the seizure recurrence rate is low in cases with single lesions; those with multiple, persistent 
or calcified lesions usually have recurrent seizures. (Singhi, 2011) 
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After the seizure of whatever cause finish, patients are probably groggy, tired, experiencing 
local or generalized headache, muscle pains, and cognitive dysfunction.  
General guidelines for immediate care of patients presenting tonic-clonic generalized 
seizures (TCGS) due to NC does not differ from general guidelines to approach patients 
with TCGS seizures due to other cause. Below, please find 15 valuable recommendations for 
the general population to support epileptic patients: 
 
1. Stay calm and protect the person experiencing the seizure 
2. Make sure he/she is breathing normally and keep the person's airway open  
3. Remove  dangerous objects that the person might  hit during the seizure 
4. Check his/her awareness by asking questions  
5. Turn the person onto his/her side. Do not hold down 
6. Inform to the patient, family, relatives or friends about what happened  
7. Loosen tight neckwear to ease breathing.  
8. Do not shake the person or shout and cushion the person's head 
9. Please describe to the doctor the ictal event.  
10. Do not insert any object in the person's mouth. 
11. Stay with the person until the seizure ends and he or she is completely alert.   
12. Offer to call a taxi, a friend, or a relative to help the person get home safely 
13. Do not restrain a person during a seizure unless there is a danger 
14. Allow them to do what they want to do 
15. Talk to patient in a soft voice to reassure them 
 
In patients presenting seizures lasting more than 20 minutes or recurrent fits without 
regaining their normal level of conscious in between, a diagnosis of status epilepticus 
should be considered. Below, please find a list of 11 medications that can be used to control 
seizures from most of etiologies.    
 
1. Lorazepam (Ativan): 0.1 mg/kg at 2 mg/min 
2. Diazepam (Valium),  10–20mg at 2–5 mg/min (Alt) 
3. Clonazepam (Klonopin) 0.5-1.0 mg three times a day up to 0.025 mg/kg; 1 mg/5 min 
(Alt) 
4. Phenytoin (Dilantin): 15–20 mg/kg not exceeding 50 mg/min in adults. Slow 
infusion rate if hypotension occurs 
5. Valproic acid (Epilim; Episenta ): 20–25 mg/kg over 5–10 min followed by 2 mg/kg/h 
6. Phosphenytoin: 15–20 mg/kg of phenytoin equivalents at 100–150 mg/min 
7. Phenobarbital: 10–20 mg/kg at 100 mg/min (Re) 
8. Midazolam: Loading dosage 0.15–0.2 mg/kg. Maintenance dosage: 0.1–0.4 mg/kg/h 
(Alt) 
9. Thiopental: 100–250mg bolus over 20 seconds then further 50mg boluses every 2–3 
min until seizure control, followed by infusion to maintain burst suppression, 
usually at 3–5 mg/kg/h (Re) 
10. Propofol: LD: 2 mg/kg, MD: 6–12 mg/kg/h (Alt) 
11. Pentobarbital (LD: 12 mg/kg, MD: 5 mg/kg/h (Re) 
12. LD: loading dose;  MD: maintenance dose;  Alt: alternative;  Re: Refractory 
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Note how long the seizure lasts and symptoms that occurred so you can get a diagnosis.  
If you see someone having a non-convulsive seizure, remember that the person's behavior is 
not intentional. The person may wander aimlessly or unusual gestures. In some epileptic 
patients you should consider some alarming signals for saving lives. Below find another 15 
recommendations.  
2.1 When do I be alarmed? 
 
1. When there are signs of cardiac or respiratory disturbances 
2. When the person does not begin breathing again  
3. When a patient does not return to consciousness after the seizure stops. 
4. When another seizure starts before the person regains consciousness. 
5. When the person is pregnant, or ethanol abused, or has diabetes mellitus.  
6. When the seizure happened in water or other dangerous situation 
7. When the seizure lasts more than five minutes (Most seizures last less than three 
minutes)  
8. When a patient has hypoglycaemia and electrolytes imbalance 
9. When the person has two or more seizures in a row.  
10. When the person has injuries from the seizure. 
11. When seizures are accompanied by progressive worsening headache 
12. When there is associate nausea, vomiting and diplopia 
13. When there is  prolonged post ictal manifestations 
14. When seizures are characterized by laryngeal constrictions, dysphagia and perioral 
paresthesia. 
15. When a patient presents comorbid mental health disorders 
 
This is a first seizure or you think it might be. If in doubt, check to see if the person has a 
medical identification card or jewelry stating that they have epilepsy or a seizure disorder. 
Timing the seizure using a watch is helpful because a brief seizure may seem longer than it 
is, so by the time an emergency medication is ready to be administered; chances are the 
seizure is over.  
2.2 Epilepsy diagnosis and treatment  
Epilepsy is a chronic brain disorder characterized by recurrent seizures with or without 
associate abnormal behavioral and other neuropsychiatric manifestations. 
About 80% of these cases can be easily treated with medication or surgery, while the 
remaining patients currently intractable. In some cases, usually involving children and 
adolescents, symptoms may simply end.  
Before diagnosing epilepsy, a thorough review of medical records of past seizures is 
consulted and blood tests are run to ensure that epilepsy is indeed the reason the seizures 
are occurring.  
Epilepsy is diagnosed by clinical assessment and its can be supported by:  
• Brain imaging  
• Electroencephalogram.  
Brain imaging is the most useful tool for clinically assessing epilepsy. When combined with 
symptom observation epilepsy experts are able to confidently diagnosis the type of epilepsy 
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and make a recommendation about how to treat the condition. The imaging techniques used 
to assess brain function vary but include CT (computed tomography) scans, fMRI 
(functional magnetic resonance imaging), or the non-visual EEG which yields graphs of 
electrical activity.  
3. Approach to patients with epilepsy and neurocysticercosis 
As mentioned in the introduction, the first line of defense against epilepsy is a 
pharmaceutical option as prescribed by their doctor. This is the least imposing on the 
patient and more often than not proves effective.  Treatment approaches to epilepsy 
secondary to NC is almost the same used in epilepsy due to other conditions. Below, are 
listed all medications more and less commonly used. We included a brand and a generic 
name because the generic usually is cheaper, sometimes by quite a lot. 
3.1 Pharmacological treatment 
Treatment of epilepsy secondary to NC differs from treatment of other causes only for the 
management of the underlying aetiology therefore we prescribe same anti-epileptic drugs 
(AED). List of medications used you can see as follow: 
 
Narrow-spectrum AEDs Broad-spectrum AEDs 
phenytoin (Epanutin ) ++ valproic acid (Epilim) + 
carbamazapine (Tegretol) (Degranol) ( Carbatrol) + lamotrigine (Lamictal) ++ 
phenobarbital (Luminal) ++ topiramate (Topamax) +++ 
oxcarbazepine (Trileptal) +++ zonisamide (Zonegran) +++ 
gabapentin (Neurontin) ++ clonazepam (Klonopin) ++ 
pregabalin (Lyrica) +++ levetiracetam (Keppra) +++ 
lacosamide (Vimpat) +++ rufinamide (Banzel) +++ 
vigabatrin (Sabril) +++  
AED  commonly used+   AED  used from time to time++   Drugs never used+++   (In our setting) 
In our experience carbamazepine (Tegretol,) is a favorite partial seizure medicine.  It affects 
sodium channels, and inhibits rapid firing of brain cells. Long-acting forms such as 
Carbatrol or Tegretol-XR can be given once a day while valproic acid is the ideal one for 
every type of motor seizures and seems to be that sodium valproate is safe and effective in 
HIV-positive patients on concurrent HAART (Yacoob, 2010). In our experience, generic 
medicine (CBZ for example) usually works well, but it may not generate the same blood 
levels as do the brand name or an alternative generic medicine and many patients are able to 
identified different effect  and their seizures are not well controlled.  We do recommend to 
epileptic patients to refill their medications form the same manufacturer and to our health 
professionals to educate their patient about this knowledge’s.  
When AED has approval for monotherapy or its benefit seems to exceed the risk, it is the best 
way of treatment. Side effects seen more often are: blurred vision, stomach upset, headaches, 
fatigue, dizziness, unsteadiness, and cognitive dysfunction. If valproic acid increases 
replication of the HIV virus or not it is not certain. Therefore, we recommend do not prescribe 
valproic acid in HIV-positive patients until this problem be completely clarified. 
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Weight gain tends to occur with Weight loss tends to occur with 
valproic acid (Depakote) topiramate (Topamax), 
gabapentin (Neurontin) zonisamide (Zonegran) 
pregabalin (Lyrica) felbamate (Felbatol). 
carbamazepine (Tegretol, Carbatrol).  
 
In endemic areas for NC once the drug has kept the patient seizure-free no less than five 
years then we recommend that the patient cease its use.  
3.2 Surgery 
The second option for treating epilepsy due to NC is usually surgery to remove giant 
subarachnoid cysts, to perform ventricular-peritoneal shunts in IV-NC or to remove the part 
or parts of the brain malfunctioning that are causing the uncontrolled seizures which is a 
very uncommon situation. 
 
Patients presenting uncontrolled fits and focal neurological signs due to associate stroke 
secondary to infective vasculitis are unsuitable for surgery.  
3.3 Implantation 
A third treatment for epilepsy due to NC is device implantation. For patients from rural 
places with high level of poverty, where local government and health authorities have other 
health priorities this procedure is practically unreachable. A vagus nerve stimulator is a 
fairly recent biomedical technology to help control seizures. Once implanted, the device 
stimulates the vagus nerve which can reduce the frequency of seizures by 30% on average if 
patients continue taking their antiepileptic medication post-implantation.  
Also from our personal experience, most of epileptic patients with NC respond very well to 
phenytoin, valproic acid or carbamazepine for control of their seizures and that is fully 
enough. We prefer valproic acid as a drug of choice for focal or generalized motor or 
myoclonic seizures in HIV-negative patients and carbamazepine for patients presenting 
focal complex seizures. Most of our general practitioner prescribes phenytoin more than 
other AED because it is inexpensive and is almost always available. 
3.4 Comments 
In our study the total scores at baseline in both groups were similar securing adequacy of 
randomization and the mild improvement observed was in relation with increased dosage 
of phenytoin. Our report provides documentation that PZQ, prednisone (PRED) and 
phenytoin (PPP) were effective in patients with NC and recurrent seizures. Using an UGH 
score as the primary outcome variable, we found a statistically significant difference 
between PPP and P. Therefore we have hypothesized about the advantages to combine the 
antiepileptic drug and antiparasitic medication for patients with recurrent seizures and NC 
mainly in endemic areas for cysticercosis; clinical manifestation of  NC is related to the 
inflammatory-immunological response of the patient when the parasite is degenerating or 
dying as result of cysticidal therapy influenced  by  the number of viable cysts, size and 
stage of the lesions, site of the cyst in the intracranial region, and the amount of re-infections 
along the time. However  many patients remain asymptomatic and the risk of intracranial 
infection after T solium egg or proglotides ingestion depend on the combination of 
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immunological status of the patient, the biological characteristic of the parasite, 
geographical and atmospherically conditions. It also serves to explain clinical differences 
and different results with the same treatment from one place to another. In places  where  
NC is endemic, other parasitic zoonoses of the brain and retroviral infections co-exist, then 
regular cycles of praziquantel and/or albendazole  and prednisone should be done precede 
by CT scan/MRI  of the brain and fundoscopy. If patients presenting more than cysts, 
fundoscopy shows intraocular parasite, or patient present signs of meningoenchephalitis 
treatment should be evaluated by a specialized health professional. This cycle should be 
repeated until that region will be covered by a good primary health care system, adequate 
level of employment and cash income, safe and clean water, proper toilet facilities, proper 
refuse disposal, electricity, telecommunication, good health education program, reform of 
animal husbandry technique, vaccination of pigs against Taenia Solium and poverty 
eradicated. (Foyaca-Sibat & Del Rio, 2007) 
The main measure to prevent Taeniosis from measly pork meat could be summarized as 
follows: 
 
Cook meat until the juices run clear or to an internal temperature of 60o C. 
Freeze pork less than 15 cm thick for 20 days at -15oC to kill any worms. 
Do not allow hogs to eat uncooked carcasses of other pigs. 
Clean meat grinders thoroughly if you prepare your own ground meats. 
Make people aware that braai, curing (salting), drying, smoking, or microwaving pork 
meat does not consistently kill parasites. 
 
Studies about treatment of NC in human beings have shown an increased level of IgG, 
interleukin-2, and neopterin in the CSF of these patients after being treated with 
praziquantel. Elevate eotaxin and interleukin-5 in serum and elevated interleukin-5 and 
interleukin-6 concentration in the CSF has been reported as well (Foyaca & Ibañez, 2003). 
In inmunodepressed patients by HIV infections or any other similar condition the parasite 
can produce more damage on the nervous tissue because there can remain viable for a 
longer period of time compared with non-inmunodepressed patient. About 10 years ago he 
has hypothesized that in those patients there is one particular stage of the parasite called  
“critical stage” (Foyaca-Sibat et al., 2001) which is  between its vesicular stage and colloid 
stage, where the releasing of taeniaestatin (serine proteinase inhibitor) is increased or is less 
destroyed, and the prostaglandins and cytokines production from the glial cells are 
importantly affected therefore a global cortical neuronal dysfunction is present affecting the 
mitochondrial activity and its ATP production, disturbance of neuronal membrane 
metabolism leading to recurrent paroxysmal activity  but whether or not the parasite is 
affected by other condition needs further research. 
In pigs affected by NC there is no evidence of seizure disorder probable because their 
neuronal membrane works differently and their mitochondrial system and supporting cell 
play a different role or simply because sodium and potassium pump works differently, we 
do not know. Therefore, deeper investigations on porcine cysticercosis probably help to 
know more about the human brain and the pathophysiology of epilepsy secondary to NC. 
In patients with insular epilepsy (laryngeal constriction, dysphagia, and peribucal 
paresthesiae) and viable cysts on the insular lobe anti-parasitic medication can cause local 
insult dysfunction leading to neurogenic heart and sudden unexpected death of epilepsy. 
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Therefore it should give with extreme caution. (Foyaca-Sibat & Ibañez-Valdés, 2006). In 
epileptic patients due to disseminate cysticercosis with cardiac involvement, cysticidal 
drugs should be used with caution because the risk of associate cardiac dysfunction; 
presence of subcutaneous cysticercosis may help suspecting that condition. (See figure 1) 
 
 
Fig. 1. Shows disseminate subcutaneous cysticercosis 
4. Conclusion 
Although treatment of NC continues to be debated, in epileptic patients should be treated 
with cysticidal medicines which are inexpensive and no complications have been reported 
(Foyaca, Ibañez & Mashiyi 2004). Below, you can see our recommendations: 
 
ABZ: 800mg daily (up 
to 30mg/kg) plus 
40mg of prednisone 
daily for no less than 
a week for IV-NC and 
SA-NC. With extreme 
caution if  cysts at 
least 50 mm in 
diameter and 
hydrocephalus is 
present (*) 
PZQ: 100mg/kg 
plus 40 mg of 
prednisone during 
two weeks or  
more for 
intraperanchymal-
NC and failure to 
ABZ (**) 
 PRED: 60-100 mg (***) 
daily for insular-NC, 
ocular-NC, 
disseminate-NC with 
cardiac involvement, 
more than 50 cysts (****)  
SA-NC, and 
meningoenchephalitis 
follow by ABZ/PZQ 
after improvement. 
In refractory 
NC, ABZ and 
PZQ should be 
combined and 
can be used for 
a longer period 
of time until 
Imagenology 
does not show 
active cysts 
 (*) Intensive medical treatment can be effective in patients with neurocysticercosis characterized by giant 
cysts. Neurosurgery may be required only when there is an imminent risk of death (Proaño, 2001; 
Göngora-Rivera, 2006). 
(**) A combination therapy for albendazole and praziquantel was statistically comparable to sole therapy 
with albendazole in eradicating lesions and preventing seizures. (Kaur et al., 2009) 
(***) Using corticosteroids at higher dosages bring the inconvenience that destruction of the parasite is 
delayed probable because most of necessary immunocomponents to participate are affected. 
(****) The combination of albendazole and surgical maneuvers to reduce intracranial pressure is a safe and 
effective method for treating severe NC (more than 100 cysticerci) proceed by higher doses of PRED; CT 
scans of the brain can be useful for its differential diagnosis. (See figure 2). The fatal prognosis is 
reported when more than 1 000 viable cysts are present (Yuan et al., 2004). 
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Fig. 2. CT scans of the brain show severe NC. 
Both drugs (PZQ/ABZ) have similar equivalent efficacy and greatly improve the 
therapeutics of cysticercosis. (Sotelo, 1988)  
If patients from endemic areas, whom have not well control of epileptic fits but not active 
cyst are seen on Imagenology, despite calcified-NCC with peripheral edema could explain 
the presence of seizure disorder, we personally recommend: 
 
One day treatment with praziquantel at doses of 100mg/kg/day divided in four 
dosages at 2/3 hours interval plus 40 mg of prednisone for three days every three to  
six months, for epileptic patients living in the endemic areas if there is not 
contraindication but fundoscopy looking for ocular cysticercosis should be performed 
before treatment. 
5. Treatment of refractory epilepsy secondary to neurocysticercosis 
Refractory epilepsy is uncommon in patients with intraperanchymal NC and when these 
patients do not respond to the first line anti-epileptic drugs other causes should be 
investigated. (Ibañez-Valdés & Foyaca-Sibat, 2006). Looking into other causes of refractory 
epilepsy we studied the first 100 consecutive patients attending to Epilepsy and NC clinic at 
Nelson Mandela Academic Hospital in South Africa presenting more than eight epileptic 
seizures per month were confirmed by neuroimaging techniques (CT and/or MRI), EEG 
and ELISA for the detection of antibody to cysticerci of Taenia solium.  Selecting criteria and 
criteria for exclusion were established as follows: 
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5.1 Subject inclusion criteria  
 
Step 1. Patients suffering from focal seizures (FS) or tonic-clonic generalized seizures 
(TCGS) according to the ILAE classification of epileptic seizures, whether or not 
secondarily generalized.  
Step 2. Diagnosed with epilepsy for no less than one year prior to be selected for this 
study 
Step 3. Epilepsy documented clinically and by paroxysmal activity on EEG. 
Step 4. Multiple 2-10 mm intracranial calcifications with or without peripheral edema on 
imagenology 
Step 5. Patient under regular treatment and good compliance for at least two months 
before the selection 
Step 6. Presenting  at least eight FS with or without generalization or six TCGS per 
month 
Step 7. Patients between 13 to 75 years old, weighed more than 50 kg 
Step 8. Signed and dated written informed consent.  
5.2 Subject exclusion criteria  
 
Pregnant patients or who are lactating. 
Subjects whose seizures cannot reliably be counted on a regular basis due to their fast and 
repetitive occurrence, severe or moderate mental retardation   and illiterate peoples 
unable to report seizures. 
History of stroke, cerebral schistosomiasis, current intracranial mass, progressive cerebral 
disease or any other progressive neurodegenerative disease. 
History of poor compliance, pseudo seizures, neuropsychiatric problems.  
Normal CT scans of the brain. 
5.3 Results and comments 
Eleven patients with NC, uncontrolled epilepsy and intracranial structural lesions were 
identified. Three had arachnoids cysts. Schizencephaly was confirmed in two, six patients 
presented SA-NC (Figure 3) and in four radiological signs of neuro-AIDS were documented 
(Figure 4). NC and associated neuron-AIDS was the commonest cause of uncontrolled 
epilepsy in this series (Table I). Arachnoids cysts often are an incidental finding on imaging 
and, usually, patients are asymptomatic even if the cyst is quite large. The most commonly 
associated clinical features are headache, calvarial bulging, and seizures, with focal 
neurological signs occurring less frequently.  
The so-called racemose variety occurs in the ventricles or basal cisterns and is characterized 
by abnormal growth of cystic membranes with degeneration of the parasite's head (scolex) 
(Bickerstaff, 1952; Rabiela, 1989). Diagnosis is based on imagenology (See figure 3). These 
cases follow a progressive course, and even after ventricular shunting, the membranes or 
inflammatory cells and proteins frequently block the shunt. 
Controversy surrounds the treatment of arachnoids cysts. Some clinicians advocate treating 
only patients with symptomatic cysts while others believe that even in asymptomatic 
patients, cysts should be decompressed to avoid future complications. The most effective 
surgical treatment appears to be excision of the outer cyst membrane and cystoperitoneal 
shunting.  
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Fig. 3. CT scans of the brain show SA-NC (Racemose’s presentation) 
Since the cyst membrane is thin and the fluid is isodense with the cerebrospinal fluid, 
uninflamed extraparenchymal cysticerci are usually not visible on CT and may only reveal 
subtle, indirect findings on MRI. Between 60% and 85% of parenchyma brain cysticerci are 
killed after standard courses of treatment, with most trials showing a higher parasiticidal 
effect of albendazole. (García, 2002). Cysts of the middle cranial fossa (50%) may compress 
the tip of the temporal lobe, displacing it in the occipital direction. This has been described 
as temporal lobe agenesis, although there is doubt as to the existence of a true temporal lobe 
agenesis. Pathologists believe that a malformation of the brain causing selective agenesis of 
the temporal does not exist. However, middle cranial fossa cysts are linked to ipsilateral 
chronic subdural hematomas. Rarely, they may communicate with the subdural space, 
forming a slight extension over the hemispheric surface. At the present moment, 
information about refractory epilepsy and SA-NC in HIV/AIDS patients is not available in 
the medical literature. 
5.4 Conclusions 
 
In absent of ischemic stroke or other 
intracranial infection: 
SA-NC in HIV/AIDS patients should be 
considered as an important cause of 
refractory epilepsy. 
6. Treatment failure and its consequences 
Albendazole has better penetration into cerebrospinal fluid; its concentration is not affected 
when given with steroids (Jung, 1990; Kim, 1999) and it is cheaper than praziquantel. 
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In our experience most of epileptic patients with active NC respond very well to first course 
of PZQ (two weeks) or ABZ (one week) if they have  less than 10 cystic lesions (sometimes 
less than 20)  in the parenchyma tissue (Foyaca-Sibat & Ibañez-Valdés, 2002). Single small 
enhancing computer tomography lesions (SSECTL) of the brain with or without peripheral 
edema, as a solitary cysticercus granuloma can be a benign form of parenchymal 
neurocysticercosis (P-NC) and it is considered to be the most common etiology for SSECTL. 
(See figure 4) 
 
 
 
Fig. 4. CT scans of the brain show SSECTL on the left frontal lobe with perilesional oedema 
In patients presenting with seizures due to single viable parenchymal neurocysticercosis, 
albendazole hastens the resolution of SSECTL if treatment is given in the early phase of 
the illness (Thussu, 2008). For patients with intraventricular NC (IV-NV) the medication 
of choice is ABZ even in HIV-positive patients (Foyaca-Sibat & Ibañez-Valdés, 2003). 
However subarachnoid neurocysticercosis (SA-NC) shows a poor response to anti-
parasitic medication and some authors reported not adequate response to ABZ, at all 
(Bandres et al., 1992; White et al., 1992; Del Brutto, 1997; Cardenas et al., 2010). Cysts in 
the basal cisterns can cause an inflammatory reaction, fibrosis and progressive thickening 
of the leptomeninges at the base of the brain.  In approximately 75% of the cases, there is a 
progressive obstacle that impedes the normal CSF circulation; resulting in obstructive 
hydrocephalus therefore we consider ventricular and basal cisternal locations as 
malignant forms of NC. 
The stages of NC before cited, are not seen in the IV-NV or SA-NC (multilocular cyst 
resembling a bunch of grapes or racemose) at the suprasellar, Sylvan and quadrigeminal 
cisterns where ABZ or PZQ does not show a good efficacy. Although resistance of 
cysticerci to ABZ in humans has never been reported, it may occur as it has been observed 
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in other related parasites (Bannur, 2001). Unfortunately, a well-designed clinical trial for 
SA-NC has not been published and the cause of the parasite's resistance to treatment, 
despite the ABZ treatment, remains unknown. We also have hypothesized about the 
immunological condition of the host, biology of the T solium, pharmacological limitation 
of the anti-parasitic drugs at subarachnoid space, and even environmental factors. These 
non-responsive cases are not the most often but their severity should encourage 
controlled studies to evaluate new forms of medical intervention and management. 
Therefore, new therapeutic approaches should be developed. Perhaps, combining 
ABZ/PZQ with ivermectine, nitazoxanide or tizoxanide will bring better results but 
because no evidence has been delivered, to perform a well-designed randomized, double-
blind placebo clinical trial is mandatory, before to deliver this recommendation. Seven 
recommendations should be considered in all cases: 
 
1. Guidelines for treatment of NC must be individualized in terms of the number and 
location of viable cysts.  
2. Growth of a parenchymal cysticercus is not a common event and may be life-
threatening.  
3. Active cystic lesions deserves active management, either with antiparasitic drugs or 
by surgical excision and epilepsy must be controlled  
4.  In epileptic patients with intracranial hypertension secondary to NC, the priority is 
to manage the raised intracranial pressure before considering any other form of 
therapy.  
5. Antiparasitic drug treatment is never the main priority in the setting of elevated 
intracranial pressure  
6. Antiepileptic drugs are the principal therapy for seizures in NC.  
7. Prophylaxis of recurrent infection based on the adequate primary health care system 
and good health education is mandatory. 
6.1 Current situation  
Conspicuously absent in the case reports available in the current medical literature are the 
following research questions: What is the prevalence of SA-NC in epileptic patients? Is SA-
NC a risk factor for ischemic stroke (IS) in epileptic population?  Does HIV comorbidity 
increases the stroke frequency in patients infected with NC?  These questions were not 
answered before, therefore the main aim of this study is to explore this inquiry and propose 
new hypotheses for future study. 
6.2 Material and method 
We  did  a cross-sectional study of patients diagnosed with NC from January 1999 to 
December 2003 at Umtata General Hospital and from January 2004 to January 2010 at 
Nelson Mandela Academic Hospital from the rural areas selected for a case control-study 
under the project: “Epilepsy and Neurocysticercosis” All patients were classified into one of 
the two respective sample groups according to presence and type of NC, all cases presented 
focal or generalized recurrent motor seizures and were grouped in  A= (SA-NC),  B= (P-NC) 
or C= (chronic headache). 
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6.2.1 Inclusion criteria 
All patients from group A met the following selection criteria:  
 
1. A positive serology ELISA test for cysticercosis 
2. CT/MRI images of the brain with intravenous contrast or gadolinium enhancement 
consistent with definitive evidence of cystic lesion (isolate or racemose) in the 
subarachnoid space without hydrocephalus and suitable to evaluate:  
• Focal arachnoiditis, when there was contrast enhancement in only one cerebral 
basal cistern. 
• Bilateral cystic lesions with diffuse arachnoiditis, in which contrast enhancement 
involved several basal cisterns. 
• Ischemic infarction, in which the number and location of cerebral lesions were 
analyzed and classified as superficial, deep no lacunar (>16 mm), and deep 
lacunar (<15 mm) at the basal ganglia, without an associate cardiac-embolic 
disease. 
3. Demographic, and associated stroke was analyzed in accordance with the presence of 
SA-NC. 
4. Recurrent  epileptic motor seizures with good compliance 
 
From the large number of patients with NC in our database we selected only a number of 
patients in group B similar to group A regarding  age and gender to assure a better 
statistical analysis and under an absolute diagnosis of intraperanchymal NC (both active 
and calcified at the same time) and epilepsy.  
All patients received 800 mg of ABZ and 40 mg of PRED per os daily during the ten days as 
part of the routine treatment for NC and 600 mg of carbamazepine daily. 
6.2.2 Exclusion criteria 
 
• Gross modifiable risk factors for stroke.  
• Heart problems or signs of infective vasculitis. 
• Suspicion of  primary or secondary vascular disease 
• Cognitive or sensory deterioration 
• Lack of check-ups (NC/SA-NC/Stroke) for more than eleven months 
• IV-NC and/or associate hydrocephalus 
• Terminal illnesses, serious psychological illnesses 
• Active addictions to psychoactive substances 
• Younger than 13 years old 
• Pregnancy  
• Lived more than six months outside of our territory.  
• HIV/AIDS in stage IV 
• No written consent 
6.2.3 Ethical aspects 
Written informed consent forms were administered in the first contact with the eligible 
patients following verbal agreement for participation. All patients were provided 
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information on the study’s purpose and procedures in addition to ethical considerations, 
including and the participant’s right to intimacy, anonymity, confidentiality, withdrawal, 
and information. Due to the large proportion of illiteracy among our population, oral 
consent observed and confirmed by an impartial witness were necessary in some cases. For 
patients selected between 1999 and 2002 only oral informed consent was taken. 
 All investigators completed the CITI training - course on the Protection of Human Research. 
All are sworn to the Hippocratic Oath and committed to respecting the norms of good 
clinical practice, as well as the requirements of the Helsinki Declaration. 
Methods for patient selection and information processing was approved by clinical 
governance at Umtata General Hospital, and the research protocol was evaluated and 
approved by Mthatha Hospital Complex, University of Transkei, and Walter Sisulu 
University IRB and the respective Ethical Committees (UGH:0001/99, UNITRA:0018/05, 
and WSU:0068/09).  
6.2.4 Data analysis 
All statistical analyses were conducted using Statistical Package for the Social Sciences 
(SPSS) version 16.0 for Windows (SPSS Inc., Chicago, Ill). Analyses were performed using an 
intention to treat bias. A descriptive analysis and an analysis of baseline comparison 
between the studies groups were performed for all study variables. To investigate the 
potential associations between ischemic stroke outcomes and the variability of NC group-
type, prevalence odds ratios at 95% confidence intervals were calculated.  
6.2.5 Results 
Out of a total of 280 eligible patients asked to participate, six patients refused to participate 
at the baseline evaluation.  Two out of the six patients agreed to participate during their 
follow-up appointment, and their data are included here (n=276).   
Group A (n=133), 70 males (52.6%) and 63 females (47.4%). Group B (n=143), 67 males 
(46.9%) and 76 females (53.1%). In total: 137 males (49.6%) and 139 females (50.4%). 
Mean age of group A: 38.63 years (13-82, SD 16.93) and group B: 37.27 years (13-80. SD 
15.43). In total, 153 serial CT/MR scans with at least 1 scan (range = 1 to 2) per subject were 
available in group A and 167 CT/MRI scans in group B, over the 10-years study period. 
In total, six patients (3.2%) with good clinical response anti-parasitic treatment developed an 
ischemic stroke (IS) while 31 (36.0%) patients with poor response developed an IS (OR: 
16.11) (6.57-39.47, IC: 95%).  See table 1 
 
   Stroke 
 Response to ABZ   Yes No 
Total 
Count 6 184 190 Yes 
% within Clinical Response 3.2% 96.8% 100.0% 
Count 31 55 86 
 Clinical Response 
No 
% within Clinical Response 36.0% 64.0% 100.0% 
Count 37 239 276  
 Total % within Clinical Response 13.4% 86.6% 100.0% 
Table 1. Clinical response 
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The risk to develop stroke was 2.82 times more in group A compared with group B. This 
suggests that although co-infection with HIV increases the risk of IS, the location of NC in 
the brain is a better predictor of IS risk than comorbidity status when there is not a good 
response to anthelmintic medicine. Taking into consideration the HIV status of patients by 
groups we found  40% of patients presented ischemic stroke (group A) and the risk to 
develop an IS among groups A and B is almost three times more. 
In group A, 19 (44.2%) patients responded poorly to anti-parasite treatment and developed 
an ischemic stroke. OR: 15.29, (4.99-46.83 IC 95%) while 12 (27.9%) from group B presented 
similar situation. OR: 15.63, (3.79-64.42, IC 95%).  (See table 2 and 3) 
 
   Stroke 
 Response to ABZ   Yes No 
Total 
Count 4 86 90 Yes 
% within Clinical Response 4.4% 95.6% 100.0% 
Count 19 24 43 
 Clinical Response 
No 
% within Clinical Response 44.2% 55.8% 100.0% 
Count 23 110 133  Total 
% within Clinical Response 17.3% 82.7% 100.0% 
Table 2. Group A  
 
   Stroke 
 Response to ABZ   Yes No 
Total 
Count 2 98 100 Yes 
% within Clinical Response 2.0% 98.0% 100.0% 
Count 12 31 43 
 Clinical Response 
No 
% within Clinical Response 27.9% 72.1% 100.0% 
Count 14 129 143  Total 
% within Clinical Response 9.8% 90.2% 100.0% 
Table 3. Group B  
After comparing all groups  with similar age, gender and HIV-positive status the risk to 
develop an IS increase to more than seven times in patients presenting SA-NC over the 
control group and almost four times in patients presenting intraperanchymal NCC. 
6.2.6 Imagenological changes after cysticidal treatment 
Twenty nine (31.9%) patients from both groups did not present imagenological changes 
after treatment and developed ischemic stroke. OR: 9.85 (4.36-22.28, IC 95%). See table 4. 
Only eight (4.3%) patients with SA-NC (Group A) presenting unequivocal imagenological 
changes after treatment and IS while 29 (31.9%) patients from the same group did not 
present changes and developed IS. In this group we found: OR= 13.15 (4.32-40.00, IC 95%).  
In group B, 10 (22.2%) patients did not present imagenological changes after treatment and 
developed IS and OR= 6.21 (1.92-20.00, IC 95%). 
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   Stroke 
Response to ABZ   Yes No 
Total 
Count 8 177 185 Yes 
% within Imagenology Changes 4.3% 95.7% 100.0% 
Count 29 62 91 
Imagenology Changes
No 
% within Imagenology Changes 31.9% 68.1% 100.0% 
Count 37 239 276 Total 
% within Imagenology Changes 13.4% 86.6% 100.0% 
Table 4. Imagenology changes. Group A 
6.2.7 Discussion and conclusion 
Commodity of T solium and HIV in epileptic patients would be expected to occur more 
frequently because of the increasing frequency of HIV infection in endemic areas of 
cysticercosis. However, little is known about the influence of HIV infection on the frequency 
of epileptic seizures and the clinical course of cysticercosis. Giant cysts and racemose forms 
of neurocysticercosis seem to be more frequent in HIV-infected patients and may be 
secondary to an uncontrolled parasitic growth because of an impaired cell-mediated 
immune response. At present we believe that toxins released by the cysticercus cause 
inflammatory changes on the perforating arteries (toxic vasculitis) at the subarachnoid space 
rather than as a direct effect on the parasite (mechanical compression). In our study, only 
one patient died from Group A and that low mortality rate may be related to the exclusion 
of patients with subarachnoid cysticercosis growing to giant size causing mass effect and 
obstructive hydrocephalus with mechanical compression. The disease course in SA-NC has 
been often long in duration and cysticerci continue to grow and proliferate through tissue 
and epilepsy control was diminished in HIV patient with an associated SA-NC and 
cerebrovascular complication as we expected. Strengths of this study include the large 
sample size, geographically distinct locations of the participating clinics, and potential 
feasibility of its replication. Weaknesses of this study include the omission of a number of 
variables that may have contributed to the analysis, especially CD-4 level and MR images.  
 
Epileptic patients with an associated SA-NC and HIV infection have a higher risk to 
develop ischemic stroke if antiparasitic treatment is not effective enough. 
7. Way forward 
At the present moment, we are investigating the effect modification of HIV-associated CNS 
diseases by parasitic zoonoses in the Eastern Cape Province; South Africa (Carabin & 
Foyaca-Sibat, 2011) and a clinical trial on cerebral toxocariasis and NC will be performed. 
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